Table 2.
Demographic and clinical characteristics of SSc subtypes
| DcSSc (n = 15) | LcSSc (n = 30) | p value | |
|---|---|---|---|
| Age (years) | 52.00 ± 9.05 | 52.00 ± 11.79 | 0.977* |
| Duration of SSc (years) | 12.93 ± 9.04 | 9.30 ± 7.61 | 0.164* |
| Age at diagnosis (years) | 38.14 ± 10.74 | 42.87 ± 11.14 | 0.192* |
| Anti-topo I positivity (SCL70) (%) | 60% | 43.3% | 0.292** |
| ACA positivity (%) | 13.3% | 30% | 0.288*** |
| ANA positivity (%) | 26.7% | 30% | 0.898*** |
| Digital ulcers (%) | 20% | 46.7% | 0.86*** |
| DMARD (%) (MTX, MMF, AZA, HCQ) | 53.3% | 53.3% | 0.997** |
SSc systemic sclerosis, DcSSc diffuse cutaneous SSc, LcSSc limited cutaneous SSc, ACA anti-centromere antibodies, anti-topo I anti-DNA topoisomerase I, ANA antinuclear antibody, DMARD disease-modifying antirheumatic drugs
The value was statistically significant (p < 0.05)
*t test
**Pearson chi-square
***Fisher exact test